Werewolf Therapeutics

61 articles about Werewolf Therapeutics

• Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting

  4/5/2024

  Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) is presenting preclinical data on development candidates WTX-518 and WTX-712 in posters at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego, California.

• Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting

  4/4/2024

  Werewolf Therapeutics, Inc. announced the publication of an abstract for an upcoming poster presentation at IMMUNOLOGYTM 2024, the annual meeting of the American Association of Immunologists taking place May 3-7 in Chicago, Illinois.

• Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

  3/7/2024

  Werewolf Therapeutics, Inc. today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023.

• Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference

  3/6/2024

  Werewolf Therapeutics, Inc. today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 9:20 AM ET on March 13, 2024, at the Leerink Partners Global Biopharma Conference, taking place March 11-13, 2024, in Miami, Florida.

• Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024

  3/5/2024

  Werewolf Therapeutics, Inc. announced the publication of abstracts for upcoming poster presentations at the American Association for Cancer Research Annual Meeting 2024, taking place April 5-10 in San Diego, California.

• Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook

  1/8/2024

  Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, provided a business update and outlined its strategic outlook and expected milestones for 2024.

• Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors

  1/4/2024

  Werewolf Therapeutics, Inc. announced the appointment of Michael B. Atkins, M.D., to its Board of Directors.

• Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference

  11/22/2023

  Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 8:20 AM ET on November 29 at the Evercore ISI HealthCONx Conference, taking place November 28-30, 2023, in Miami, Florida.

• Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

  11/14/2023

  Werewolf Therapeutics, Inc. provided a business update and reported financial results for the third quarter ended September 30, 2023.

• Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

  11/3/2023

  Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced preliminary first-in-human clinical data from initial monotherapy dose-escalation cohorts in the Company’s lead clinical program, WTX-124x2101.

• Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

  10/31/2023

  Werewolf Therapeutics, Inc. today announced that a poster describing interim first-in-human clinical results from initial monotherapy dose-escalation cohorts in the ongoing Phase 1/1b study of WTX-124 will be presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting, taking place November 1-5, 2023 in San Diego, California.

• Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

  9/27/2023

  Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced the publication of abstracts for upcoming poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting, taking place November 1-5, 2023 in San Diego, California.

• Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124Virtual event to be held on Monday, September 18, 2023, at 10:00 am ET

  9/11/2023

  Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that it will host a virtual R&D Event on Monday, September 18, 2023, at 10:00 am ET.

• Werewolf Therapeutics to Participate in Upcoming September 2023 Investor Conferences

  9/5/2023

  Werewolf Therapeutics, Inc. announced that management will participate in the following upcoming investor conferences in the month of September:

• Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

  8/10/2023

  Werewolf Therapeutics, Inc. today provided a business update and reported financial results for the second quarter ended June 30, 2023.

• Werewolf Therapeutics to Present at the 2023 Jefferies Healthcare Conference

  6/1/2023

  Werewolf Therapeutics, Inc. announced that management will present a company overview at 4:00 PM ET on June 8 at the Jefferies Healthcare Conference, taking place June 7th-9th, 2023, in New York, NY.

• Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

  5/11/2023

  Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, provided a business update and reported financial results for the first quarter ended March 31, 2023.

• Werewolf Therapeutics to Participate in May Investor Conferences

  5/1/2023

  Werewolf Therapeutics, Inc. today announced that management will participate at the following conferences in the month of May.

• Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE™ Molecule, in Cancer Immunology Research

  4/19/2023

  Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics, announced the publication in Cancer Immunology ResearchOnline First of preclinical data for mWTX-330, a systemically delivered Interleukin-12 (IL-12) INDUKINETM molecule.

• Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

  3/23/2023

  Werewolf Therapeutics, Inc. today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022.